Search

Your search keyword '"Cannella, Laura"' showing total 165 results
Start Over Author "Cannella, Laura" Publication Type Academic Journals
165 results on '"Cannella, Laura"'

5. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol

Author

Efficace, Fabio, Boccadoro, Mario, Palumbo, Antonio, Petrucci, Maria Teresa, Cottone, Francesco, Cannella, Laura, Zamagni, Elena, Niscola, Pasquale, Kyriakou, Charalampia, Caravita, Tommaso, Offidani, Massimo, Mandelli, Franco, and Cavo, Michele

Published
2018
Full Text
View/download PDF

9. Lifestyle Behaviors and Health-Related Quality of Life in Long-Term Survivors of Acute Myeloid Leukemia: An International Survivorship Study By the Gimema, EORTC Quality of Life and Leukemia Groups

Author

Efficace, Fabio, Cannella, Laura, Thomas, Xavier, Yuksel, Meltem Kurt, Trisolini, Silvia Maria, Saveria, Capria, Brini, Alberto, Audisio, Ernesta, Maurillo, Luca, Lemoli, Roberto Massimo, Imovilli, Annalisa, Panovska Stavridis, Irina, Quattrone, Martina, Ciccone, Maria, Filardi, Nunzio, Fracchiolla, Nicola, Vallisa, Daniele, Crugnola, Monica, Melillo, Lorella Maria Antonia, Skerget, Matevz, Vignetti, Marco, and Baron, Frederic

Published
2023
Full Text
View/download PDF

21. Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long‐term follow up of a phase III study.

Author

Baron, Frédéric, Efficace, Fabio, Cannella, Laura, Muus, Petra, Trisolini, Silvia, Halkes, Constantijn J. M., Fazi, Paola, Vignetti, Marco, Marie, Jean‐Pierre, Chiusolo, Patrizia, Velden, Walter, La Sala, Edoardo, Vitolo, Umberto, Thomas, Xavier, Lefrère, Francois, Di Raimondo, Francesco, Bourhis, Jean‐Henri, Specchia, Giorgina, Guimarães, José E., and Allione, Bernardino

Published
2020
Full Text
View/download PDF

22. P1686: LONG‐TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY.

Author

Efficace, Fabio, Cannella, Laura, Thomas, Xavier, Yüksel, Meltem Kurt, Trisolini, Silvia Maria, Brini, Alberto, Audisio, Ernesta, Maurillo, Luca, Lemoli, Roberto M., Imovilli, Annalisa, Panovska‐Stavridis, Irina, Pagano, Livio, Ciccone, Maria, Filardi, Nunzio, Fracchiolla, Nicola Stefano, Vallisa, Daniele, Crugnola, Monica, Cascavilla, Nicola, Skerget, Matevz, and Vignetti, Marco

Published
2023
Full Text
View/download PDF

24. Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study

Author

Baron, Frederic, Efficace, Fabio, Cannella, Laura, Mandelli, Franco, Willemze, Roelof, Muus, Petra, Marie, Jean-Pierre, Ferrero, Dario, Dictus, Marlies, Fazi, Paola, La Sala, Edoardo, Bourhis, Jean-Henri, Fabbiano, Francesco, Bosi, Alberto, Sborgia, Marco, Martinelli, Giovanni, Bron, Dominique, Petti, Maria C., Halkes, Constantijn J.M., van der Velden, Walter J.F.M., Boccadoro, Mario, Amadori, Sergio, Zittoun, Robert A., and Suciu, Stefan

Published
2016
Full Text
View/download PDF

29. Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma -- a case report.

Author

Gruszka, Alicja M., Rabascio, Cristina, Cannella, Laura, Sammassimo, Simona, Andreola, Giovanna, Gregato, Giuliana, Faretta, Mario, Calleri, Angelica, De Molfetta, Rita, Pruneri, Giancarlo, Bertolini, Francesco, and Alcalay, Myriam

Subjects
CHRONIC myeloid leukemia, T-cell lymphoma, PROTEIN-tyrosine kinases, NEOPLASTIC cell transformation, TUMOR diagnosis, PATIENTS
Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm underlain by the formation of BCR-ABL1 -- an aberrant tyrosine kinase -- in the leukaemic blasts. Long-term survival rates in CML prior to the advent of tyrosine kinase inhibitors (TKIs) were dismal, albeit the incidence of secondary malignancies was higher than that of age-matched population. Current figures confirm the safety of TKIs with conflicting data concerning the increased risk of secondary tumours. We postulate that care has to be taken when distinguishing between coexisting, secondary-to-treatment and second in sequence, but independent tumourigenic events, in order to achieve an unbiased picture of the adverse effects of novel treatments. To illustrate this point, we present a case of a patient in which CML and peripheral T-cell lymphoma (PTCL) coexisted, although the clinical presentation of the latter followed the achievement of major molecular response of CML to TKIs. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

31. Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Author

Breccia, Massimo, Baccarani, Michele, Rosti, Gianantonio, Cottone, Francesco, Cannella, Laura, Guilhot, François, Vignetti, Marco, and Efficace, Fabio

Subjects
PHYSICIANS' attitudes, MYELOID leukemia, NILOTINIB, DASATINIB, PROTEIN-tyrosine kinases, PATIENTS
Abstract

We investigated factors that physicians consider of most importance in the selection of second line tyrosine kinase inhibitors treatments (TKIs) in chronic myeloid leukemia patients (CML). [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

Author

Loglisci, Giuseppina, Breccia, Massimo, Nanni, Mauro, Mancini, Marco, De Cuia, Rosa, Cannella, Laura, Salaroli, Adriano, Federico, Vincenzo, Serrao, Alessandra, Giovanna loglisci, Maria, Santopietro, Michelina, and Alimena, Giuliana

Subjects
LETTERS to the editor, CHRONIC myeloid leukemia, DRUG resistance in cancer cells, GENETICS, PATIENTS
Abstract

A letter to the editor is presented which discuses a case study of a 69-year-old woman diagnosed with chronic myeloid leukemia (CML) who had been dasatinib-resistant resulting to Philadelphia (Ph) chromosome isodicentric duplication.

Published
2011
Full Text
View/download PDF

33. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.

Author

Breccia, Massimo, Cannella, Laura, Stefanizzi, Caterina, Latagliata, Roberto, Nanni, Mauro, Diverio, Daniela, Santopietro, Michelina, Federico, Vincenzo, and Alimena, Giuliana

Abstract

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and 400 mg/day is considered the standard dose. Although it is generally well tolerated, some patients require temporary drug discontinuation and permanent dose reduction because of haematological or non-haematological toxicities. Whether or not reduced doses are effective as the standard dose in inducing and/or maintaining complete cytogenetic and molecular response is not clear. We report the outcome of 45 CML patients in early (17) and late (28) chronic phase (CP) in whom, within a series of 250 patients treated with imatinib, reduced the dose of the drug after experiencing adverse events. Median time interval between the start of therapy and dose reduction was 58 days, whereas median administered dose was 300 mg/day. At 6 months from reduction, major cytogenetic responses (MCRs) were observed in 67% of patients, with 58% being complete cytogenetic remission (CCR), and complete molecular response (CMR) were obtained in 18% of patients. At 12 months, all patients who had obtained MCR reached CCR: this was significantly higher in low risk patients (87%) versus non-low risk patients (66 and 46%), and in early phase (82%) versus late phase (53.5%). CMR and major molecular response (MMR) were detected in 20 and 22% of patients, respectively. Low dose imatinib appears effective in patients with intolerance to standard dose, even though long-term effects remain to be established. Copyright © 2009 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

34. Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.

Author

Breccia, Massimo, Latagliata, Roberto, Cannella, Laura, Carmosino, Ida, Santopietro, Michelina, Loglisci, Giuseppina, Federico, Vincenzo, and Alimena, Giuliana

Subjects
DYSPLASIA, APLASTIC anemia, HEMORRHAGE, ACUTE myeloid leukemia, PATIENTS
Abstract

According to the revised WHO classification of 2008, dysplasia in ≥10% of one bone marrow lineage and one cytopenia constitutes the low-risk category of unilineage cytopenia and unilineage dysplasia (UCUD). We retrospectively reclassified, according to WHO, low-risk MDS from our database and found 126 subjects with these features at diagnosis: 79 patients were categorized as refractory anemia (RA), 23 patients as refractory neutropenia (RN), and 24 as refractory thrombocytopenia (RT). We did not find differences between the three subgroups as regards sex, median age, and cytogenetic aberrations. Lower PMN count (0.8 × 109/L) was observed in the RN category, as well as lower platelet count in the RT category (51 × 109/L). Moreover, we found a lower rate of patients requiring RBC transfusions, during the disease course, in the RT category (45.8%) as compared to RA (62%) and RN (69%) groups ( p = 0.05); a lower incidence of infections at diagnosis in the RT category (20.8%) compared to RA (32%) and RN (43%) categories ( p = 0.03); and a higher incidence of hemorrhagic symptoms at diagnosis in the RT category (41.6%) and RN category (26%) as compared to the RA group (5%) ( p = 0.001). Application of different scoring systems (Bournemouth and Spanish scores, WPSS) revealed a low OS in high-risk patients within the RT category, compared to RA and RN categories, although unlikely to reflect the consequences of low OS found in the former category. Statistically significant differences were also evidenced in the incidence of acute myeloid leukemia (AML) evolution and overall survival: 7/79 (8%) patients with the RA category evolved to AML in a median time of 89 months, whereas 4/23 (17%) of the RN category and 1/24 (4%) of the RT category experienced disease progression, in a median time of 33.8 and 12.8 months, respectively ( p = 0.03). The RT category had a lower overall survival (15.9 months) as compared to RA (48.2 months) and RN (35.9 months) categories ( p < 0.001). In conclusion, in our study, application of the revised 2008 WHO classification confirmed the importance of separating patients with unilineage dysplasia for prognostic disease assessment; from our results it seems that the RT category has a worse outcome. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

35. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients.

Author

Breccia, Massimo, Frustaci, Anna Maria, Cannella, Laura, Stefanizzi, Caterina, Latagliata, Roberto, Cartoni, Claudio, Diverio, Daniela, Guarini, Anna, Nanni, Mauro, Rago, Angela, Cimino, Giuseppe, and Alimena, Giuliana

Abstract

Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2009
Full Text
View/download PDF

36. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.

Author

Breccia, Massimo, Stefanizzi, Caterina, Cannella, Laura, Latagliata, Roberto, Frustaci, Anna Maria, Carmosino, Ida, Santopietro, Michelina, and Alimena, Giuliana

Subjects
IMATINIB, ANTINEOPLASTIC agents, MYELOID leukemia, PROTEIN-tyrosine kinases, HEMATOLOGICAL oncology, TOXICITY testing
Abstract

Imatinib is a relatively specific inhibitor of the BCR/ABL tyrosine kinase, effective in chronic myeloid leukemia (CML). The aim of our study was to analyse the frequency and type of hematological and non-hematological adverse events in our series of late and early chronic phase patients with CML treated with imatinib and correlate the grade of hematological toxicity with the response obtained. Hematological events were seen in 59 out of 150 (39%) late chronic phase (CP) patients: of these, 24% experienced toxicity Grade 3-4. Of the 100 early CP patients, 26 (26%) had hematological adverse event: 7% experienced toxicity Grade 3-4 (p = 0.0001). We found that only in early CP patients, the occurrence of hematological side effects of any grade within 6 months of therapy had a negative influence on cytogenetic response. We compared the incidence of non-hematological adverse events occurring in late and in early CP patients and found that in these latter, some side effects were more frequent, such as weight gain, periorbital edema, muscle cramps, skin rashes, diarrhea, weeping. On the contrary, we found that bone pain and hemorrhagic events were more common in late CP patients. Grade 3-4 adverse events were recorded at rates below 4% and decreased over time: in late CP patients hemorrhages and muscle cramps were the most common side effects of Grade 3-4, whereas in early CP patients, the most frequent events were nausea, weight gain and cutaneous rash. We have observed that hematological and non-hematological side effects during imatinib therapy are different among late and early CP patients and that severe hematological toxicity may influence cytogenetic response only in early CP patients. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

50. Familial occurrence of myelodysplastic syndrome with del(5q).

Author

Volpicelli, Paola, Latagliata, Roberto, Carmosino, Ida, Breccia, Massimo, Vozella, Federico, Mancini, Marco, Cannella, Laura, and Alimena, Giuliana

Subjects
LETTERS to the editor, MYELODYSPLASTIC syndromes, PATIENTS
Abstract

A letter to the editor is presented regarding the familial occurrence in patients with myelodysplastic syndromes (MDS) with chromosome 5 or del (5q).

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results